We successfully created and characterized a patient-specific LMNA-KI in vitro model that provided a comprehensive basis to understand cellular changes arising from an LMNA-KI mutation in a patient with severe and treatment-resistant familial DCM, and then allowed us to provide a well-tolerated, focused, and ultimately successful therapeutic approach. Here, PSME3 is linked to familial dilated cardiomyopathy.